Fasoracetam (NFC-1 / NS-105)
Non-selective agonist of metabotropic glutamate receptors (mGluR groups I, II, and III) with secondary cholinergic and GABAergic modulation. Upregulates GABA-B receptor expression, which is the primary mechanism of interest for ADHD-associated glutamatergic dysfunction. Originally developed by Nippon Shinyaku for vascular dementia. Phase I data exists. A small pediatric ADHD pilot (NFC-1) showed signal in mGluR-mutant genotypes.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- alt
- ast
- creatinine
- pregnancy
- lactation
- concurrent-gabapentinoid-use
- PMID:29260819A randomized, double-blind, placebo-controlled trial of NFC-1 for ADHD with mGluR mutations — Nat Med, 2018
- PMID:8788029Effects of NS-105 on learning and memory in rodent models — Jpn J Pharmacol, 1996
- PMID:9495878NS-105 enhances choline acetyltransferase and nerve growth factor in basal forebrain — Brain Res, 1998
Fasoracetam is the racetam that almost became a drug. Twice. Nippon Shinyaku abandoned it after Phase I for vascular dementia. Then Aevi Technologies (now Cerecor) picked it up for ADHD, specifically in children with mGluR network gene mutations. The 2018 Nature Medicine pilot showed meaningful signal in that genetic subpopulation. The GABA-B upregulation mechanism makes it theoretically useful for phenibut withdrawal, which is how most of the community actually uses it. A compound designed for dementia, tested for ADHD, deployed for GABAergic recovery. Pharmacology rarely follows a straight line.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Fasoracetam (NFC-1 / NS-105) in a protocol matched to you